FDA Clears Conditional MRI Use for Implantable Sleep Apnea System
Conditional use of full-body magnetic resonance imaging (MRI) is reportedly permitted for patients using any of the models for the remede® System, an implantable nerve stimulation therapy indicated for the treatment of adults with moderate to severe central sleep apnea.
The Food and Drug Administration (FDA) has expanded the 510(k) clearance for the remede® System (Zoll Medical Corporation), an implantable therapy for central sleep apnea, to include conditional use with magnetic resonance imaging (MRI).
An implantable transvenous phrenic nerve stimulation therapy, the remede System originally received FDA clearance in 2017 for the treatment of adults with moderate to severe central sleep apnea. The expanded FDA clearance allows the conditional use of full-body MRI for all models of the remede System, according to Zoll Medical Corporation.
Asim Roy, M.D., said the expanded FDA clearance for conditional MRI use, is a significant development for those with sleep apnea and other comorbidities.
“Patients with central sleep apnea often suffer from other comorbidities that may benefit from MRI scanning including, but not limited to, brain, spine and joint issues,” noted Dr. Roy, the medical director of the Ohio Sleep Medicine Institute in Dublin, Ohio. “Approval of the remede System for conditional use with MRI will allow those patients to now have access to this important therapy.”
(Editor’s note: For related content, see “SNMMI Meeting: New Cardiac PET Study Shows that Severe Obstructive Sleep Apnea Doubles the Risk of Impaired Myocardial Blood Flow.”)
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
